FDA approves Junshi, Coherus’ PD-1 toripalimab for nasopharyngeal carcinoma – Endpoints News

by

  1. FDA approves Junshi, Coherus’ PD-1 toripalimab for nasopharyngeal carcinoma Endpoints News
  2. Coherus rejects ‘heavily discounted’ pricing on Loqtorzi, the first China-made PD-1 drug to win FDA nod FiercePharma
  3. FDA Approves Loqtorz Regimens for Advanced Nasopharyngeal Carcinoma Curetoday.com
  4. Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Yahoo Finance
  5. Peninsula drug maker Coherus wins FDA cancer drug approval, extends one lease, exits other space – San Francisco Business Times The Business Journals
  6. View Full Coverage on Google News

Read original article here

Leave a Comment